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thelium, but also by cardiac sympathetic nerve endings (3). This
promotes norepinephrine release in myocardial ischemia, thus
contributing to reperfusion arrhythmias (4). Bradykinin-induced
norepinephrine release in the heart is potentiated by cyclooxygen-
ase products (5). Because aspirin inhibits cyclooxygenase, one
would expect aspirin to diminish the bradykinin-induced, norepi-
nephrine release from cardiac adrenergic terminals. Indeed, we
have found this to be the case with indomethacin, another
cyclooxygenase inhibitor (5). Endothelial dysfunction is known to
occur in atherosclerotic coronary artery disease, myocardial isch-
emia and heart failure (6,7). Therefore, in these disease states, the
prostacyclin- and nitric-oxide–mediated endothelium-dependent
cardioprotective effects of bradykinin are likely to be attenuated,
and the deleterious effects of bradykinin-induced norepinephrine
release predominate. In fact, coronary arteries with dysfunctional
endothelium are hypersensitive to the vasoconstricting effects of
catecholamines (8). Thus, the improved survival demonstrated by
Leor et al. (1) may be due to an aspirin-induced reduction of
norepinephrine release within the heart. Indeed, in the Evaluation
of Losartan in the Elderly (ELITE) study (9), plasma norepineph-
rine was found to be increased in patients treated with the ACE
inhibitor captopril, but decreased in those treated with the angiotensin
receptor antagonist losartan. Increased plasma norepinephrine is
associated with a greater risk of cardiovascular morbidity and mortality
(10). In the ELITE study, patients taking captopril had a higher
mortality rate than those taking losartan (9). Accordingly, decreased
norepinephrine release could well be an important mechanism asso-
ciated with the lower mortality found by Leor et al. (1) in patients
treated with ACE inhibitors and aspirin in combination.
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REPLY
We thank Levi et al. for their thoughtful comments. They
proposed a fresh explanation to our clinical observation (1).
Although previous data suggest a negative interaction between
aspirin and angiotensin-converting enzyme (ACE) inhibitors (2),
Levi et al. propose a “positive” interaction. We (1) and others (2)
were not aware of the mechanism proposed by Levi et al. They
suggest that bradykinin facilitates norepinephrine release from
cardiac sympathetic nerves during ischemia, and this effect is
potentiated by ACE inhibition (3,4). Aspirin might attenuate
bradykinin-mediated norepinephrine release from nerve endings
during myocardial ischemia. A reduction in plasma norepinephrine
might be beneficial owing to the deleterious effects of norepineph-
rine on the heart. Thus, aspirin may prevent one of the adverse
effects of bradykinin during myocardial ischemia. The mechanism
proposed by Levi et al. to explain our findings is unique and attractive,
but is derived from an isolated guinea pig heart model and specimens
of the human right atrium. Thus, these exciting findings need
confirmation in a clinical trial that will also evaluate the appropriate
dose of aspirin in patients treated with ACE inhibitors.
The neurohormonal activation in patients with heart failure or
myocardial ischemia is complex and sometimes contradicts our
conventional understanding. For example, we are disappointed by
the preliminary results of the recent Moxonidine Congestive Heart
Failure Trial (MOXCON) study (5). The study was terminated
early, and the investigators failed to confirm the hypothesis that a
reduction in plasma norepinephrine by moxonidine can reduce
mortality in patients with heart failure.
Data derived from the Evaluation of Losartan in the Elderly
(ELITE-2) study, which compared mortality in patients treated with
captopril versus losartan, and data from the Warfarin-Antiplatelet
Trial Chronic Heart Failure (WATCH) trial, which evaluates aspirin,
clopidogrel or warfarin in patients with heart failure, may help to
clarify the controversy surrounding the relation between aspirin and
ACE inhibitors. Until then, on the basis of our observation (1) and
the findings of Levi et al. (3,4), we suggest that administration of low
dose aspirin to patients taking ACE inhibitors is safe and may have an
additive beneficial effect during myocardial ischemia.
Jonathan Leor, MD, FACC
Shmuel Gottlieb, MD
Solomon Behar, MD
Department of Cardiology
Soroka Medical Center
P.O. Box 151
Beer Sheva 84105, Israel
E-mail: jleor@bgumail.bgu.ac.il
PII S0735-1097(99)00616-6
818 Letters to the Editor JACC Vol. 35, No. 3, 2000
March 1, 2000:815–23
REFERENCES
1. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in
patients treated with angiotensin-converting enzyme inhibitors—a co-
hort study of 11,575 patients with coronary artery disease. J Am Coll
Cardiol 1999;33:1920–5.
2. Teerlink JR, Massie BM. The interaction between ACE-inhibitors and
aspirin in heart failure: torn between two lovers. Am Heart J 1999;138:
193–7.
3. Hatta E, Maruyama R, Marshall SJ, Imamura M, Levi R. Bradykinin
promotes ischemic norepinephrine release in guinea pig and human
hearts. J Pharmacol Exp Ther 1999;288:919–27.
4. Seyedi N, Maruyama R, Levi R. Bradykinin activates a cross-signaling
pathway between sensory and adrenergic nerve endings in the heart: a
novel mechanism of ischemic norepinephrine release? J Pharmacol Exp
Ther 1999;290:656–63.
5. Coats AJ, Coats AJ. Heart Failure 99—The MOXCON Study. Int J
Cardiol 1999;71:109–11.
Mercury and Idiopathic
Dilated Cardiomyopathy
We read with interest the recent report on trace metals and
idiopathic dilated cardiomyopathy by Frustaci et al. (1). As far as
we know, this is the first report to show that markedly increased
concentrations of mercury (Hg) in cardiac tissue are associated
with a specific cardiac pathology.
A recent review cites a number of studies that clearly establish
that the largest source of nonoccupational Hg exposure for the
general population is their dental amalgam fillings (2). At least
70% of all Hg ions excreted in human urine originate solely from
amalgam fillings (3). Therefore, we wonder if it would be possible
for Frustaci et al. to obtain dental histories for their patients.
The suggestion offered by Frustaci et al., that Hg11 acts as a
Ca11 antagonist at the actin–myosin junction, thereby inhibiting
sarcomere contraction and ultimately myocyte function, is certainly
a possibility. Another possibility they might wish to consider is
that Hg causes disruption of the microtubule structure, a major
cytoskeletal component of most cells. We have demonstrated this
phenomenon in brain neurons where Hg inhibits guanosine
triphosphate nucleotide binding to beta-tubulin, thereby blocking
an essential step in the polymerization of tubulin molecules for
microtubule formation (4). Perhaps the same phenomenon also
occurs in myocardial cells.
We encourage Frustaci et al. to pursue the matter of dental histories
for their patients, which may account for the inordinately high levels
of Hg (22,000 times greater than that in control subjects) seen in the
heart tissue of patients with idiopathic dilated cardiomyopathy.
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We thank Drs. Lorscheider and Vimy for their observations.
Sarcotubular abnormalities were a common ultrastructural finding
in our patients with idiopathic dilated cardiomyopathy, and they
may well be related to the extremely high level of mercury in the
myocardiocytes. Alterations of beta-tubulin interfering with mi-
crotubule organization were reported in idiopathic as well as
anthracycline-associated dilated cardiomyopathy (1,2).
As far as the possible origin of mercury from dental amalgam is
concerned, we failed to include dental history in the patient
questionnaire assessing the environmental exposure to heavy met-
als and toxic trace elements. However, at a recent follow-up, of the
original group of 13 patients with idiopathic dilated cardiomyop-
athy, 10 (three patients died in the meantime) were specifically
questioned about their dental history, five of whom had dental
amalgam fillings, but their myocardial mercury concentrations
were not significantly higher than that of the others. Finally, the
simultaneous myocardial increase of antimony, and to a lesser
extent of silver, arsenic, gold, chromium, lanthanum and zinc, in
these patients, as well as the concentration of normal trace
elements in their skeletal muscle biopsies, makes the pathogenetic
role of a dental mercury source rather unlikely.
A cell membrane dysfunction, possibly induced by a myocardial
viral infection, such as coxsackie B virus, might be a more plausible
explanation.
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